Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System

StockNews.AI • 19 hours

BullishShort TermCorporate DevelopmentsSENS N/A

High Materiality9/10

Information

twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM twiist™ ...

AI Summary

Senseonics has partnered with Sequel MedTech to integrate their Eversense 365 Continuous Glucose Monitoring (CGM) system with the twiist AID insulin delivery system. This milestone allows patients to enjoy an innovative one-year glucose monitoring solution, expected to be widely available by March 2026, enhancing diabetes management efficiency.

Trading Thesis

Investment in SENS is recommended due to strategic integration enhancing market position.

Market-Moving

Integration with twiist AID may significantly boost Eversense 365 adoption.
Expected March 2026 availability could generate positive market momentum.
The product integration could influence insurance coverage and reimbursement.
Potential for increased sales with unique one-year CGM solution.
Sequel's advanced technology may attract new investors to SENS.

Key Facts

Eversense 365 is the only FDA-approved implantable CGM for a year.
The integration with twiist AID enables automated insulin delivery.
The twiist system uses iiSure technology for precise insulin measurement.
Expected availability of the integrated system is March 2026.
Eversense requires periodic fingerstick calibrations for accuracy.

Companies Mentioned

Senseonics Holdings, Inc. (SENS): Focuses on innovative diabetes management technologies.
Sequel MedTech, LLC (N/A): Develops insulin delivery technologies, enhancing SENS's offerings.

Corporate Developments

The integration falls under 'Corporate Developments' as it represents significant product innovation that could disrupt the market for diabetes management systems, positioning SENS advantageously against competitors.

FAQ

Why Bullish?

This integration could position SENS favorably in the growing diabetes management market, similar to prior successful product launches in medical technology sectors.

How important is it?

This partnership represents a major breakthrough in product capability, likely leading to increased revenue and market visibility for SENS.

Why Short Term?

Broad availability expected soon could lead to immediate market reactions and investor interest.

Related Companies

SENS N/A

Senseonics and Sequel MedTech Launch Integrated Diabetes Management System

GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a pioneering medical technology company, has announced the first commercial patients utilizing the Eversense 365 Continuous Glucose Monitor (CGM) in conjunction with the Sequel twiist™ Automated Insulin Delivery (AID) system. This strategic integration marks a significant advancement in diabetes management, providing enhanced flexibility and personalization for individuals with type 1 diabetes.

Revolutionizing Diabetes Management

The integration of the Eversense 365 CGM with the twiist AID system represents a groundbreaking milestone, being the first instance where a one-year sensor has been paired with an AID. This development is expected to minimize the inconveniences associated with regular sensor changes and re-pairing, while maintaining exceptional accuracy in glucose monitoring.

First implantable CGM: Eversense 365 is the only CGM that can be implanted, offering one year of uninterrupted monitoring.
iiSure™ technology: The twiist AID system utilizes advanced technology for precise insulin delivery measurements.
Real-time data: The system harnesses real-time sensor readings to automatically adjust insulin delivery based on predicted glucose levels.

Quotes from Leadership

Tim Goodnow, President and CEO of Senseonics, emphasized the collaboration’s impact: “While our technologies are unique, our goal is the same - to improve lives and reduce complexity for patients living with diabetes. We are proud to partner with Sequel and provide the necessary glucose monitoring data to power the twiist Loop algorithm, enabling real-time insulin delivery decisions.”

Alan Lotvin, CEO of Sequel MedTech, highlighted the commitment to personalized diabetes management: “Diabetes management is deeply personal, and no single approach works for everyone. Our focus on personalization means Sequel is committed to creating choice for people living with diabetes.”

Availability and Future Outlook

The broad availability of the twiist™ AID system integrated with Eversense 365 is anticipated by March 2026. For further details regarding availability, interested parties can visit Eversense CGM Partners or twiist.com.

About Eversense and Senseonics

The Eversense 365 CGM, developed by Senseonics, is known for its innovative design and long-term usability, offering glucose monitoring for up to one year. This technology helps enhance the quality of life for patients by significantly reducing the frequency of sensor changes.

Senseonics Holdings, Inc. is dedicated to transforming diabetes care through long-term, implantable glucose management solutions. The Eversense systems feature a small sensor that communicates with a smart transmitter worn externally, sending glucose data to a mobile app every five minutes.

Forward-Looking Statements

Statements in this release concerning future expectations and plans for Senseonics, including the partnership with Sequel MedTech to integrate their products, may involve forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may significantly differ due to various factors, including uncertainties in integration processes and regulatory challenges.